{"entity":{"id":"niguarda-cancer-center","kind":"institution","name":"Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda","aka":["Ospedale Niguarda","Niguarda Ca' Granda Hospital","Falck Division of Medical Oncology"],"tldr":"Milan's largest public hospital, whose cancer centre under Salvatore Siena and Andrea Sartore-Bianchi ran HERACLES, the trial that proved HER2 is a target in bowel cancer.","summary":"The Niguarda Cancer Center is the oncology department of Milan's Niguarda hospital, a large public teaching hospital of the University of Milan. Under Salvatore Siena it built a programme in molecular oncology of colorectal cancer, running HERACLES, the first trial to show that HER2-directed therapy works in HER2-amplified colorectal cancer, contributing to the panitumumab trials that established RAS testing, and hosting the phase 1 unit that led DESTINY-CRC01. Andrea Sartore-Bianchi directs its clinical research and precision oncology programme.","asOf":"2026-09-18","links":[{"label":"Ospedale Niguarda","url":"https://www.ospedaleniguarda.it"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["heracles"],"people":["salvatore-siena","andrea-sartore-bianchi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milan","country":"IT","lat":45.51,"lng":9.19,"institutionType":"hospital","website":"https://www.ospedaleniguarda.it","university":"Università degli Studi di Milano","programs":["Colorectal cancer molecular oncology","Phase 1 trials","Precision oncology"]},"route":"/institutions/niguarda-cancer-center/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"trial":[{"id":"heracles","kind":"trial","name":"HERACLES","route":"/trials/heracles/"}],"person":[{"id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","route":"/people/andrea-sartore-bianchi/"},{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","route":"/people/salvatore-siena/"}],"paper":[{"id":"paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015","kind":"paper","name":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","route":"/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/"},{"id":"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","kind":"paper","name":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)","route":"/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/"},{"id":"paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","kind":"paper","name":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","route":"/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/"}]}}